India’s pharmaceutical market is expanding rapidly, driven by demographic shifts, rising burden of chronic diseases, and increasing demand for accessible, high-quality healthcare. However, persistent gaps in early diagnosis, continuity of care, and affordability continue to challenge the healthcare ecosystem. These dynamics underscore the need for timely, scalable, and patient-centric solutions.
This evolving landscape is driving a shift toward a more integrated care approach and innovation tailored to India’s diverse healthcare needs.
Our India Region Formulations (IRF) business is at the forefront of this transformation, consistently outperforming the market through data-driven solutions, strong execution, and strategic partnerships.
Our leadership is anchored in deep expertise and strong market presence across our key therapy areas, enabling us to deliver cutting-edge patient outcomes while sustaining competitive advantage in the Indian pharma market.
8th largest company in the Indian Pharmaceutical Market (IPM)
5 Lupin brands ranked in top 300 IPM brands
#1 in Anti-TB, #2 in Respiratory segment, #3 in both Anti-Diabetes and Cardiology
5 flagship brands - Gluconorm-G, Budamate, Huminsulin, Ivabrad, and Rablet ranked in the top 300 IPM
19 brands featured in Top 500 IPM
Supported by 350,000+ HCPs across India
Lupin’s IRF business delivers a strong portfolio of generics with leading therapies across Diabetes, Cardiology, Gastroenterology, Respiratory, and more, improving affordability and everyday access to care.
In the biosimilars segment, Etanercept is Lupin’s flagship injectable biologic for chronic immune-mediated inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and plaque psoriasis, addressing significant unmet patient needs. These capabilities are anchored in Lupin Biotech, our dedicated research and state-of-the-art manufacturing platform focused on developing high-quality biosimilars at scale.
Complementing this, Lupin continues to expand its footprint in complex specialty drugs, including inhalation therapies and innovative combinations, strengthening long-term, patient-centric healthcare solutions.
Anya is India’s first Al-powered, multilingual health chatbot, offering medically verified answers and a safe space for all users. Accessible 24/7 on WhatsApp, Anya chatbot responds in 20+ languages and delivers solutions across 17 therapy areas.
Our India business focuses on key therapy areas, aiming to deliver affordable care with quality and trusted outcomes for people.
We rank #3 in the Anti-Diabetic market in India and manufacture14 of the top 20 anti-diabetic molecules in the country. Two of our diabetes medicines (Gluconorm-G and Huminsulin) rank among the top 300 brands in the Indian Pharma Market.
Our Anti-Diabetes portfolio addresses multiple disorders such as type 2 diabetes mellitus, type 1 diabetes mellitus, and diabetes related cardiometabolic risks.
Our approach to diabetes care goes beyond medication. Our patient support program, HuMrahi offers personalized counselling and support, and has impacted 200,000+ patients till date.
Collectively, our initiatives strengthen our role in delivering comprehensive and integrated diabetes care across the patient journey.
Lupin is committed to extending care beyond prescriptions through patient-centric programs that empower individuals and improve health outcomes. From setting up 10,000+ health camps to battle diabetes and cardiac conditions to India's 1st digital asthma educator platform, our deep patient engagement and purpose-driven innovation are bringing us one step closer to a healthier world.
